


<b>TRANSMISSION OF INFORMATION DISCLOSURE STATEMENT</b> <b>(Under 37 CFR 1.97(b) or 1.97(c))</b>				Docket No. <b>RLL-275US</b>	
<small>Int'l Application of:</small> <b>SINGH et al.</b>					
<b>Application No.</b> <b>10/522,223</b>	<b>Filing Date</b> <b>January 24, 2005</b>	<b>Examiner</b> <b>TBA</b>	<b>Customer No.</b> <b>26815</b>	<b>Group Art Unit</b> <b>TBA</b>	<b>Confirmation No.</b> <b>TBA</b>
<b>Title: PROCESSES FOR THE PREPARATION OF ORAL DOSAGE FORMULATIONS OF MODAFINIL</b>					
<p style="text-align: center;">Address to:</p> <p style="text-align: center;"><b>Commissioner for Patents</b>  <b>P.O. Box 1450</b>  <b>Alexandria, VA 22313-1450</b></p>					
<b>37 CFR 1.97(b)</b>					
<p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p>					
<b>37 CFR 1.97(c)</b>					
<p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p>					
<p style="margin-left: 20px;"><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p>					
<p style="margin-left: 40px;"><b>OR</b></p>					
<p style="margin-left: 20px;"><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p>					



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: SINGH et al.

Serial No.: 10/522,223

Examiner: TBA

Filing Date: January 24, 2005

Group Art Unit: TBA

Title: PROCESSES FOR THE PREPARATION OF ORAL DOSAGE FORMULATIONS OF MODAFINIL

CERTIFICATE OF MAILING

I certify that the following correspondence:

- Transmittal of Information Disclosure Statement
- Information Disclosure Citation
- Copies of cited references
- Postcard

is being deposited on April 27, 2005 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Box 313(b) Washington, D.C. 20231.

  
Kim Campbell

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
 MAY 02 2005  
 (Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
 RLL-275US

In Re Application: SINGH et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/522,223	January 24, 2005	TBA	26815	TBA	TBA

Title: PROCESSES FOR THE PREPARATION OF ORAL DOSAGE FORMULATIONS OF MODAFINIL

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of \_\_\_\_\_ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. as described below.
  - Charge the amount of \_\_\_\_\_
  - Credit any overpayment.
  - Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

April 27 2005

(Date)

Kim Campbell

Signature of Person Mailing Correspondence

Kim Campbell

Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

William D. Hare  
 Signature

Dated: April 26, 2005

William D. Hare, Esq.

Reg. No. 44,739

Customer No. 26815

CC:


## INFORMATION DISCLOSURE CITATION

Docket No.: RLL-2005-US Serial No.: 10/522,223

Applicants: SINGH et al.

Filed: 1/24/2005

Group:



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	RE37,516	1/15/2002	Grebow et al.	514	618	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES <input type="checkbox"/> NO <input type="checkbox"/>
	B1	WO 02/30414	4/18/2002	PCT	A61K	31/165	<input type="checkbox"/>
	B2	WO 02/96401	12/5/2002	PCT	A61K	31/165	<input type="checkbox"/>
	B3	FR 2 702 968	9/30/1994	France	B01J	2/00	<input type="checkbox"/>
	B4	GB 2 293 103	3/20/1996	UK	A61K	9/14	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Anonymous, "Provigil -TM (modafinil) Tablets" Internet Article Online! 1998, retrieved from the internet: < <a href="http://www.fda.gov/cder/foi/label/1998/207171bl.pdf">http://www.fda.gov/cder/foi/label/1998/207171bl.pdf</a> >

EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.